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Primary PCIAbstract Background: Patients with ST-segment elevation myocardial infarction (STEMI) and
multivessel coronary artery disease are common. It is unknown whether complete revascularization
in these patients is superior.
Objectives: This study evaluated the short term outcome of culprit only revascularization com-
pared to total revascularization in the setting of primary percutaneous coronary intervention in
patients with STEMI.
Methods: The study included 40 patients with acute STEMI who were presented within 12 h from
onset of symptoms. All patients had multivessel disease on emergency coronary angiography. Pri-
mary PCI was performed in all patients. According to study protocol, patients were divided into 2
groups: group A (20 patients) included patients who underwent culprit artery only revasculariza-
tion, while group B (20 patients) had total revascularization. In-hospital and 30 days outcome (mor-
tality, re-infarction, heart failure, recurrence of angina symptoms, cerebrovascular stroke, need for
revascularization) were reported.
Results: All cause mortality was reported in one patient from group B (5%). No re-infarction.
Recurrence of ischemic symptoms was reported in 15% of patients (25% versus 5% in groups A
and B respectively, P= 0.2). Heart failure was evident in 15% of all patients (15% in each group).
Composite end point of adverse cardiovascular events was reported in 37.5% of all patients (40%
versus 35% in groups A and B respectively, P = 0.5). Contrast induced nephropathy was evident in
354 M. Salem et al.47.5% of patients (10% versus 35% in groups A and B respectively, P = 0.08), subacute stent
thrombosis occurred in 2 patients (5%), (10% in group B but not in group A, P = 0.4).
Conclusion: Both treatment strategies carry equivalent short term outcome among patients with
STEMI treated with PPCI.
ª 2014 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
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nd/4.0/).1. Introduction
Primary percutaneous coronary intervention (PPCI) is the
most effective available method to reestablish coronary perfu-
sion in patients presenting with STEMI. It is associated with
greater patency of infarct related artery and lower rates of
death, re-infarction and stroke when compared to fibrinolysis.1
The prevalence of multivessel disease (MVD) in patients
presented with STEMI approaches 40%.2 The conventional
strategy of PPCI in the setting of STEMI usually involves
selective intervention of infarct related artery (IRA, culprit
only revascularization) with treatment of significant lesions
in non-IRA in patients with MVD, to be performed later as
staged PCI procedure (staged revascularization).3 Early revas-
cularization of IRA by PPCI is recommended according to
recent guidelines. But strategy for treatment of non-IRA
lesions in the acute setting remains unclear.4
In this prospective, controlled study we compared short
term outcome between PPCI to IRA (culprit only revasculari-
zation) and that for both infarct related artery and noninfarct
related artery (total revascularization) in STEMI patients with
MVD.
2. Patients and methods
2.1. Study design
This prospective, controlled, nonrandomized study included
40 patients with STEMI who were admitted to the coronary
care unit of cardiology department at the National heart insti-
tute, Egypt, during the period from October 2010 to March
2012. All patients signed an informed consent and the study
was approved by the local ethics committee. Key inclusion
criteria were as follows: 1. STEMI patients presented within
12 h of onset of symptoms. 2. MVD disease on coronary angi-
ography, which are suitable for PCI. MVD was defined as the
presence of at least one lesion P70% diameter stenosis in a
major epicardial vessel, or one of its branches other than the
infarct related artery (IRA). Key exclusion criteria were as
follows: cardiogenic shock, pulmonary edema, severe renal
impairment (creatinine >3.0 mg/dl), any contraindication to
anti platelet therapy, left main coronary artery disease,
patients in whom non-IRA is <2.5 mm, or is totally occluded
or showing extensive calcification.
2.2. Methods
2.2.1. Baseline evaluation
All patients had review of their medical history on admission
to emergency department including the following: analysis of
demographic data (age, sex), presence of risk factors ofcoronary atherosclerosis, associated comorbidities, general
and cardiac examination, 12 leads ECG which was performed
immediately on admission and every 6 h during the first 24 h,
and once daily until discharge, routine laboratory investiga-
tions including the following: cardiac biomarkers (Troponin I
& CK-MB), kidney function tests (S. Creatinine), lipid profile
including (total cholesterol, low density lipoprotein (LDL) high
density lipoprotein (HDL), triglycerides), random blood sugar.
2.2.2. Coronary angiography and PPCI
Aspirin (300 mg loading dose, then 150 mg daily) and clopido-
grel (600 mg loading then 150 mg/day maintenance dose) were
given on admission. Un-fractionated heparin (UFH) (10,000
units) bolus dose was injected after sheath insertion. The proce-
dure was performed according to the standard technique for
coronary angiography and PCI. Femoral approach was used
in all patients using 6–7 Fr sheaths. Diagnostic coronary angi-
ography was done to detect the culprit vessel and eligibility to
the study. XB guiding catheters were used for left coronary
lesions and JR catheters for right coronary lesions. Aspiration
devices and glycoprotein inhibitors were used in lesions with
heavy thrombus burden and or impaired TIMI flow after PCI.
Bare metal stents (BMS) were used in all patients. The operator
determined the size and length of the stent. Sheaths were
removed 6 h after PCI and compression was done manually.
2.2.3. Study protocol
After diagnostic coronary angiography, patients were subse-
quently divided into the following:
Group A: culprit only revascularization (COR).
Group B: total revascularization (TR).
2.2.4. Study end points
Thirty days combined end point of all cause mortality,
re-infarction, heart failure, recurrence of angina symptoms,
cerebrovascular stroke, need for revascularization (Repeat
PCI or bypass surgery).
2.2.5. Study definitions
1. Contrast induced nephropathy: 25% rise in serum creati-
nine from baseline within 48–72 h from the procedure.
2. Major bleeding: intracranial bleeding, GIT bleeding,
decrease hemoglobin concentration by more than 5 gm/dl.
3. Minor bleeding: puncture site bleeding, decrease hemoglo-
bin concentration by less than 3 gm/dl.
4. Reinfarction: recurrent chest pain associated with new
ECG changes such as ST segment re-elevation or new path-
ologic Q waves.
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after stent implantation with TIMI 3 flow, but without pro-
cedure related complications.
3. Statistical analysis
Data are presented as mean ± SD for continuous data and as
number (%) for categorical data. Between groups analysis was
done using student t-test for continuous data and Chi-square
test (or Fischer exact test) for qualitative data. Level of evi-
dence was detected to be significant at P value <0.05. Data
were collected and analyzed by SPSS (version 17).
4. Results
4.1. Study population
The mean age was 56 ± 10 years (59.05 ± 10.2 years versus
53.1 ± 10.7 y in groups A and B respectively, P = 0.08),
80% were males (60% versus 90% in groups A and B respec-
tively, P = 0.23). All data are presented in Table 1. Between
groups comparison did not show statistically significant differ-
ences in baseline characteristics.
4.2. Clinical presentation on admission
Chest pain was the main symptom on admission in all patients
(100%), 35% of patients were presented with dyspnea (30% in
group A versus 40% in group B, P = 0.5), 22.5% of patients
were presented with palpitations (15% in group A versus
30% in group B, P = 0.4).
4.3. Clinical examination on admission
The mean heart rate was 98.7 ± 32.4 bpm (92 ± 29 versus
106 ± 35 bpm in groups A and B respectively, P = 0.15),
the mean systolic blood pressure was 150 ± 23 mmHg
(139 ± 21 mmHg versus 160 ± 19 mmHg in groups A and B
respectively, P = 0.02), the mean diastolic blood pressure
was 89 ± 10 mmHg (84.5 ± 11 mmHg versus 93 ± 8 mmHg,
in groups A and B respectively, P = 0.03).Table 1 Baseline characteristics of study population.
All patients G
n= 40 n
Age mean ± SD 56.07 ± 10.71 5
Male sex, n (%) 32 (80%) 1
Family history of CAD 8 (20%) 3
DM 21 (52%) 8
Hypertension 32 (80%) 1
Smoking 32 (80%) 1
Dyslipidemia 20 (50%) 1
Prior CAD 28 (70%) 1
Prior PCI 2 (5%) 0
Prior CABG 0 (0%) 0
CAD: coronary artery disease.
PCI: percutaneous coronary intervention.
DM: diabetes mellitus.
CABG: coronary artery bypass grafting.4.4. Site of infarction detected by ECG
Fifty-seven percent (57%) had anterior infarction (50% versus
65% in groups A and B respectively, P= 0.2), inferior infarc-
tion was reported in 40% of patients (50% versus 30% in
groups A and B respectively, P = 0.1). Lateral infarction
was evident in only 1 patient (5%) from group B.
4.5. Time from onset of symptoms to admission
The mean time was 7.1 ± 2.7 h in all patients (7.7 ± 2.9 h in
group A, versus 6.45 ± 2.4 h in group B, P = 0.16), 40% of
all patients were presented less than 6 h (35% versus 45% in
groups A and B respectively, P = 0.5).
4.6. Door to balloon time
The mean door to balloon time was 80.2 ± 38.5 min in all
patients (87 ± 44.5 min in group A, versus 73.5 ± 31.1 min
in group B, P = 0.3) Fig. 1.
4.7. Coronary angiography before PPCI
Two vessel disease was reported in 65% of all patients, and 3-
vessel disease in 35% of patients. The culprit artery was left
anterior descending (LAD) in 55% of all patients (45% versus
65% in groups A and B respectively, P= 0.3), right coronary
artery (RCA) was the culprit artery in 35% of patients (45%
versus 25% in groups A and B respectively, P = 0.39), while
left circumflex (LCX) was the culprit artery in 10% of patients
(10% in each group). Noninfarct related artery was LAD in
15% of patients (15% in each group), while RCA in 27.5%
of all patients (30% versus 25% in groups A and B
respectively, P= 0.8), LCX in 22.5% of patients (20% versus
25% in groups A and B respectively, P = 0.81), while LAD
and LCX were present in 10% of all patients (15% versus
5% in groups A and B respectively), LCX and RCA were
present in 25% of all patients (20% versus 30% in groups A
and B respectively, P = 0.8). Thrombolysis in myocardial
infarction (TIMI) flow before PCI was zero in 70% of all
patients (65% versus 75% in groups A and B respectively
P = 0.4), while TIMI flow 1 was reported in 30% of allroup A Group B P value
= 20 n= 20
9.05 ± 10.22 53.10 ± 10.71 0.08
4 (60%) 18 (90%) 0.23
(15%) 5 (25%) 0.4
(40%) 13 (65%) 0.11
4 (70%) 18 (90%) 0.23
4 (70%) 18 (90%) 0.23
1 (55%) 9 (45%) 0.52
6 (80%) 12 (60%) 0.16
(0%) 2 (10%) 0.48
(0%) 0 (0%) –
Figure 1 Door to balloon time.
Table 2 Coronary angiography before PPCI.
All patients Group A Group B P value
n = 40 n= 20 n = 20
TIMI flow before PCI
0 28 (70%) 13 (65%) 15 (75%) 0.5
I 12 (30%) 7 (35%) 5 (25%)
Culprit artery
LAD 22 (55%) 9 (45%) 13 (65%) 0.4
RCA 14 (35%) 9 (45%) 5 (25%)
LCX 4 (10%) 2 (10%) 2 (10%)
Other noninfarct related artery
LAD 6 (15%) 3 (15%) 3 (15%) 0.8
RCA 11 (27.5%) 6 (30%) 5 (25%)
LCX 9 (22.5%) 4 (20%) 5 (25%)
LAD – LCX 4 (10%) 3 (15%) 1 (5%)
LCX – RCA 10 (25%) 4 (20%) 6 (30%)
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P = 0.4) Table 2.
4.8. Procedural data
Femoral approach was done in all patients. Predilatation was
done in 55% of all patients, aspiration devices were used in
12.5% of all patients, glycoprotein inhibitors were used in
50% of all patients (40% versus 60% in groups A and B
respectively, P = 0.2). The mean number of stents implanted
was 1.8 ± 0.3, 1.2 ± 0.1, 2.5 ± 0.9 in all patients, groups A
and B respectively. The number of stents was one stent in
42.5% of all patients (85% versus 0% in groups A and B
respectively, P = 0.001), two stents in 35% of all patients
(15% versus 55% in groups A and B respectively), three stents
were implanted in 20% of all patients (0% versus 40% in
groups A and B respectively), while four stents were implanted
in 2.5% of patients (0% versus 5% in groups A and B respec-
tively). The mean stent length was 21.8 ± 5.6 mm
(23.95 ± 5.11 mm versus 20.7 ± 5.6 mm in groups A and B
respectively, P = 0.03). The mean stent diameter was
2.87 ± 0.28 mm (3.0 ± 0.3 mm versus 2.8 ± 0.28 mm in
groups A and B respectively, P = 0.01). TIMI flow in the cul-
prit artery after PPCI was III in 97.5% of all patients (95%
versus 100% in groups A and B respectively), TIMI flow II
in 2.5% of all patients (5% versus 0% in groups A and Brespectively). The mean procedural time was 47.7 ± 13.5 min
in all patients (41.5 ± 8.5 min versus 54 ± 14.7 min in groups
A and B respectively, P = 0.003), the mean contrast volume
was 215 ± 78.6 ml (172.5 ± 73.4 ml versus 257.5 ± 59.1 ml
in groups A and B respectively, P= 0.001). No reported cases
of procedure related complications in either group.
4.9. In hospital outcome
No reported cases of cardiogenic shock, stroke, or major
bleeding in either group. Recurrence of angina pain was
reported in 7.5% of all patients (10% versus 5% in groups
A and B respectively, P = 0.8), minor bleeding occurred in
17.5% of all patients (10% versus 25% in groups A and B
respectively, P= 0.1), contrast induced nephropathy was evi-
dent in 23% of patients (10% versus 35% of groups A and B
respectively, P = 0.08) with a mean serum creatinine
0.9 ± 0.3 mg%, 1.3 ± 0.5 mg% in groups A and B respec-
tively. Subacute stent thrombosis occurred in 2 patients (5%)
(10% of group B but not in group A, P = 0.4), in the two
patients, stent thrombosis occurred in LAD which was the cul-
prit artery and was treated by re-intervention. One patient in
group B (5%) had sudden cardiac death but not in group A,
heart failure occurred equally in both groups (10%).
4.10. 30 days outcome
Combined end point of adverse cardiovascular events was
reported in 43% of all patients (40% versus 45% in groups
A and B respectively, P = 0.6). All cause mortality occurred
in one patient from group B (5%). Re-infarction was evident
in 2 patients from group B but not in group A. Recurrence
of angina pain was reported in 15% of patients (25% versus
5% in groups A and B respectively, P = 0.2). Heart failure
was evident in 15% of all patients (15% in each group), the
need for re-intervention was reported in 10% of patients in
group B but not in group A, no reported cases of cerebrovas-
cular stroke.
5. Discussion
Prior studies suggest that acute coronary syndromes, including
acute myocardial infarction (AMI), may result from a systemic
inflammatory process, causing multiple unstable lesions. Thus,
a strategy of multivessel PCI in the peri-infarct period may be
important in improving the outcomes of PPCI. Such an
attempt of complete revascularization may prevent recurrent
ischemia from ‘non-infarct-related’ lesions, obviating the need
for repeat intervention, and also possibly improves the late
outcome by reducing the ischemic burden following myocar-
dial damage.5
This study evaluated the short term outcome of culprit only
revascularization compared to total revascularization in the
setting of STEMI with MVD. We reported higher incidence
of stent thrombosis and contrast induced nephropathy in
patients who were assigned to total revascularization. However
this was not of significant differences. In addition, we did not
report significant differences in 30 days outcome between both
treatment strategies.
Anterior wall infarction was reported in 55% of patients.
Prior trials2,3,6,7 reported similar incidence of anterior
Culprit lesion versus total revascularization in primary PCI 357infarction. We reported 2-vessel disease and 3-vessel disease in
65%, and 35% of the study population respectively. In the
study by Toma et al.6, 2-vessel disease represented 68%, while
3-vessel disease represented 32%. However, Di Mario et al.2
showed that 2-vessel disease was evident in 53% and 3-vessel
disease in 47%. This variation in the number of vessels affected
may be explained by the difference in the profile of risk factors
between different studies. The mean PCI time was significantly
longer in patients assigned to total revascularization
(54 ± 14 min) versus 41.5 ± 8.5 in those who had culprit only
PCI. In addition, there was larger volume of contrast material
in total revascularization patients (257 ml) compared to culprit
only patients (172 ml). This was logic, because some extra time
and contrast were needed to treat the nonculprit artery lesions.
The mean number of stents was 1.8 ± 0.3, 1.2 ± 0.1,
2.5 ± 0.9 in all patients, groups A and B respectively. In other
studies2,8, the number of stents per patient in COR group was
1.76 ± 1.1 versus 2.9 ± 1.3 in TR patients. We reported
higher incidence of stent thrombosis in TR group (10%) while
no stent thrombosis occurred in COR group (0%). This could
be related to the higher number of stents in TR group with
associated hypercoagulable state in these patients. In addition,
the small sample size in our study compared to others, and dif-
ference in study population may have an impact Contrast
induced nephropathy in TR group (35%) was more frequent
than COR patients (10%). Larger amount of contrast used
in the TR patients is the main obvious cause. Prior trials3,9,10
suggested that multivessel intervention in patients not in
cardiogenic shock undergoing PPCI did not improve the
in-hospital outcomes, and was also associated with a longer,
more complex procedure, increased radiation exposure and
increased incidence of acute renal failure secondary to
increased contrast dye load.
We did not report differences between both treatment strat-
egies considering the 30 days outcome except that more
patients in COR group had recurrent chest pain but without
statistically significant difference between groups.
Prior trials11–13 revealed that 30 days follow-up of patients
who underwent TR had more fatal re-infarction and more
adverse events than patients who underwent COR strategies.
However, others14,15 found that multivessel approach had bet-
ter outcome by decreasing the need for further revasculariza-
tion. Recently, a meta analysis16 reported that, if multivessel
PCI during index catheterization was performed, hospital mor-
tality was increased (OR 1.35, 95% CI 1.19–1.54, P < 0.001).
However, when multivessel PCI was performed as a staged
procedure, hospital mortality was lower (OR 0.35, 95% CI
0.21–0.59; P < .001; P < 0.001). The differences in both in-
hospital and 30 days outcome between previously mentioned
studies may be explained by the differences in study popula-
tions, sample size, associated co-morbidities, left ventricular
functions, lesions complexity, skills of the operators, and
finally the after PCI care.
6. Conclusion
In patients with STEMI and MVD undergoing PPCI, com-
plete revascularization strategy has similar 30 days outcome
compared to a strategy of culprit lesion only revascularization.
Higher rates of stent thrombosis and CIN were observed in
complete revascularization strategy.7. Recommendation
Further studies with larger sample size are required to evaluate
safety and efficacy of infarct-related artery only PCI compared
to total revascularization in the setting of STEMI patients with
MVD.
8. Study limitation
Small sample size and lack of randomization may have impact
on the validity of our results due to possible investigators bias
in analyzing the results. In addition, short follow-up period is
considered another limitation of the study.
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